Compare GSK plc (GSK) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Sprott Uranium Miners ETF — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while Sprott Uranium Miners ETF trades at $49.22. The key difference: GSK plc pays a 3.49% dividend while Sprott Uranium Miners ETF pays none, and GSK plc is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| GSK | URNM | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $61.18 | $83.99 |
52-Week Low | $36.20 | $44.14 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
URNM (Sprott Uranium Miners ETF) trades at $49.49, down 4.07% today amid bearish technical signals with all 15 moving averages indicating sell signals. The ETF provides concentrated exposure to uranium miners, benefiting from the nuclear energy revival driven by AI power demand. Recent news highlights uranium's strategic role in meeting data center electricity needs, though the sector experienced recent volatility with uranium stocks declining.
The uranium sector faces a decade-long supply-demand imbalance favoring miners, though URNM's pure-miner focus brings higher volatility. Key risks include uranium price fluctuations and miner operational challenges. Analyst sentiment is mixed with some seeing long-term opportunity while others caution about stretched valuations relative to underlying uranium prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
